Filtered By:
Specialty: Infectious Diseases
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 11695 results found since Jan 2013.
Advancement of Computational Design Drug Delivery System in COVID-19: Current Updates and Future Crosstalk- A Critical update
Infect Disord Drug Targets. 2023 Aug 16. doi: 10.2174/1871526523666230816151614. Online ahead of print.ABSTRACTPositive strides have been achieved in developing vaccines to combat the coronavirus-2019 infection (COVID-19) pandemic. Still, the outline of variations, particularly the most current delta divergent, has posed significant health encounters for people. Therefore, developing strong treatment strategies, such as an anti-COVID-19 medicine plan, may help deal with the pandemic more effectively. During the COVID-19 pandemic, some drug design techniques were effectively used to develop and substantiate relevant critica...
Source: Infectious Disorders Drug Targets - August 16, 2023 Category: Infectious Diseases Authors: Abu Mohiuddin Sumanta Mondal Source Type: research
Physical therapy rehabilitation after hospital discharge in patients affected by COVID-19: a systematic review
In 2019, the Coronavirus (SARS-CoV-2) virus was identified, also defined as novel coronavirus or severe acute respiratory syndrome coronavirus 2. The Corona VIrus Disease (COVID-19) pandemic generated several ...
Source: BMC Infectious Diseases - August 16, 2023 Category: Infectious Diseases Authors: Perez A. M. C., Silva M. B. C, Mac êdo L. P. G., Chaves Filho A. C., Dutra R. A. F and Rodrigues M. A. B. Tags: Research Source Type: research
Reflections on Participation in a Trial on Hydroxychloroquine as Prevention for COVID-19 among Health Workers in Niger
Am J Trop Med Hyg. 2023 Aug 14:tpmd220606. doi: 10.4269/ajtmh.22-0606. Online ahead of print.ABSTRACTIn 2020, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a rapidly emerging virus causing the coronavirus disease 2019 (COVID-19) pandemic, had no known effective prophylaxis and no widely available proven effective antiviral treatment. Hydroxychloroquine/Chloroquine was identified as an early potential therapeutic candidate drawing on evidence from reports of both in vitro and in vivo testing. A multicountry placebo-controlled randomized trial was set to evaluate the use of hydroxychloroquine/chloroquine to p...
Source: Am J Trop Med Hyg - August 14, 2023 Category: Infectious Diseases Authors: Youssouf Kabore Renaud Vatrinet Ousmane Guindo Souleymane H Moussa William H K Schilling Rebecca F Grais Source Type: research
SARS-CoV-2 seroprevalence in pregnant women during the first three COVID-19 waves in The Gambia
SARS-CoV-2, the causative agent of the coronavirus disease 2019 (COVID-19), was first identified in December 2019 in Wuhan, China [1]. SARS-CoV-2 was rapidly transmitted globally, disrupting structures and systems; and causing millions of deaths. Globally, there were 278.7M COVID-19 cases and 5.39M attributable deaths by December 2021 [2], 21 months after the World Health Organization (WHO) declared COVID-19 a pandemic [3]. Nigeria reported the first case in Sub-Saharan Africa (SSA) on 28 January 2020 [4].
Source: International Journal of Infectious Diseases - August 14, 2023 Category: Infectious Diseases Authors: Ramatoulie E. Janha, Alasana Bah, Hawanatu Jah, Fatima Touray, Yahaya Idris, Saikou Keita, Yassin Gaye, Samba Jallow, Tisbeh Faye-Joof, Baboucarr Njie, Rachel Craik, Nuredin I. Mohammed, Peter von Dadelszen, Umberto D'Alessandro, Anna Roca, the PRECISE Ne Source Type: research
Sampling from upper and/or lower respiratory tract when diagnosing coronavirus disease 2019 (COVID-19) – results from a Danish cohort study
.
Source: Infectious Diseases - August 11, 2023 Category: Infectious Diseases Authors: Line StormMette Toftgaard RoensboSimon Kok JensenSteffen LethS øren Jensen-FangelMarianne Kragh Thomsena Department of Clinical Microbiology, Aarhus University Hospital, Aarhus N, Denmarkb Department of Infectious Diseases, Aarhus University Hospital, Aa Source Type: research
Comparing the Effectiveness of Bivalent and Monovalent COVID-19 Vaccines against COVID-19 Infection during the Winter Season of 2022 –2023: A Real-World Retrospective Observational Matched Cohort Study in the Republic of Korea
The coronavirus disease 2019 (COVID-19) omicron variants became dominant in 2022, with Omicron BA.5 accounting for the majority of sequenced viral genomes worldwide at the end of the year [1]. To address concerns about immune escape induced by the emergence of novel variants, bivalent vaccines were developed by Pfizer/BioNTech and Moderna. These vaccines contain mRNA encoding the ancestral strain and either omicron subvariant BA.1 or BA.4/BA.5 [2]. In the Republic of Korea, bivalent vaccines targeting BA.1, developed by Moderna and Pfizer/BioNTech, were separately approved on September 08, 2022 and October 07, 2022.
Source: International Journal of Infectious Diseases - August 10, 2023 Category: Infectious Diseases Authors: Chungman Chae, Ryu Kyung Kim, Eun Jung Jang, Ji Ae Shim, Eunkyung Park, Kil Hun Lee, Sye Lim Hong, Asma Binte Aziz, Birkneh Tilahun Tadesse, Florian Marks, Sangwoo Tak, Sangwon Lee, Donghyok Kwon Source Type: research
Vaccine-induced and hybrid immunity to SARS-CoV-2 after three or four doses of BNT162b2 - results from 22 months follow-up of a healthcare workers cohort, Israel, 2020-2022
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has killed at least seven million worldwide since its emergence in China in late 2019 [1] and became the most significant global health crisis since the 1918 influenza pandemic [2]. In order to mitigate the spread of the pandemic, non-pharmaceutical interventions such as protective equipment and social distancing as well as the rapid development and mass implementation COVID-19 vaccines, have been rolled out to prevent death, reduce the spread and severity of disease, and protect healthcare systems from becoming overwhelmed [2].
Source: International Journal of Infectious Diseases - August 10, 2023 Category: Infectious Diseases Authors: Michael Edelstein, Karine Wiegler Beiruti, Hila Ben-Amram, Netta Beer, Christian Sussan, Perachel Batya, Salman Zarka, Kamal Abu Jabal Source Type: research
